MI-EATON
6.9.2022 12:31:56 CEST | Business Wire | Press release
Power management company Eaton will display its Vehicle Group's innovative portfolio of internal combustion solutions for commercial vehicles Sept. 20-25 at the IAA Transportation show in Hannover, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220906005013/en/
Eaton’s Vehicle Group offers a portfolio of technologies that reduce emissions and improve fuel economy in commercial vehicles today and well into the future. (Photo: Business Wire)
"Although the transition to electrification is progressing, OEMs continue to seek improvements in fuel emissions and consumption for internal combustion engines," said Traci Melville, senior vice president and general manager, Global Products, Eaton's Vehicle Group. "In fact, according to KGP Powertrain Intelligence, there will be more than 30 million commercial vehicles produced with a diesel engine over the next decade."
Variable Valve Actuation technologies are flexible, reduce emissions
Eaton's Variable Valve Actuation (VVA) solutions are flexible and adaptable to any valvetrain architecture, allowing OEM customers to implement one or multiple functions that can significantly reduce carbon dioxide (CO2) and nitrogen oxides (NOx) emissions and lower fuel use.
Cylinder deactivation keeps selective catalytic reduction (SCR) at optimal temperatures by operating just two or three cylinders rather than all six in light-load conditions. That effectively delivers higher exhaust temperatures from the functioning cylinders at low speeds and loads or when the truck is neutral coasting, two conditions that can quickly cool aftertreatment systems. Concurrently, cylinder deactivation also lowers fuel consumption.
Late intake valve closing improves the engine's thermal efficiency, enabling a higher compression ratio, which reduces CO2 emissions and increases exhaust gas temperature that contributes to aftertreatment performance.
TVS EGR pump more controllable than competitive offerings
Eaton's positive-displacement TVS® exhaust gas recirculation (EGR) pump enables the use of a high-efficiency turbo to reduce engine pumping losses and increase fuel economy. The TVS® EGR pump is driven by a 48-volt electric motor, making it completely independent from engine speed and significantly more controllable than pumpless EGR systems.
Decompression engine brake compact, integrates into small engines
Eaton's decompression engine brake technology enhances brake power in the full engine operating range and is compact for easy integration into smaller engines.
Eaton's engine decompression brake is a valvetrain system with a mechanism to quickly switch between driving and engine braking mode according to customer requirements and can be integrated into a standard assembly.
Eaton's valves operate in demanding engine applications
Eaton offers a portfolio of differing valves, including monometallic and bimetallic, solid and hollow sodium cooled, seat faced and coated, providing a suitable solution for all vehicle applications. Eaton is developing new valve technologies for future commercial vehicles, including those with hydrogen internal combustion engines (ICE). Unlike traditional diesel-powered commercial vehicle engines, hydrogen ICE powertrains can operate dry combustion at extremely elevated temperatures depending on engine calibration.
Eaton is leveraging its nearly 100 years of experience in valve production to support hydrogen applications and the next generation of diesel engines. One possible solution is a sodium-filled hollow valve, which enables internal cooling. Wear protection is ensured by selecting the proper materials and coatings among the several grades available in Eaton's portfolio.
Eaton, Tenneco offer exhaust thermal management system to reduce emissions
Eaton and Tenneco launched a joint development agreement between Eaton's Vehicle Group and Tenneco's Clean Air business to produce an integrated exhaust thermal management system that enables commercial truck manufacturers to meet upcoming emissions regulations.
The integrated exhaust thermal management system provides heat directly to the vehicle's aftertreatment system, which is essential for reducing harmful exhaust emissions. Eaton's electrically driven TVS® blower precisely controls the airflow so the system can maintain optimal aftertreatment temperatures.
48-volt electric catalyst heater controller provides precise aftertreatment control
Eaton offers an air-cooled electric catalyst heater controller as part of its broader 48-volt electrical system portfolio. It contains several technologies that allow manufacturers to integrate 48-volt architectures into next-generation commercial vehicles. The controller manages the power delivered to the aftertreatment heater and is designed to receive commands from the aftertreatment system and provide soft-start and soft-stop capabilities for maintaining system voltage control.
48-volt DC-DC Converter for dual-voltage electrical systems
Eaton is developing a DC-DC Converter for 48V system architectures that will enable future powertrains to comply with new emissions regulations and provide higher levels of electrical power for CO2 reduction and autonomous driving systems. Unlike competitive offerings, Eaton's DC-DC converters are operational in ambient temperatures up to 85 degrees Celsius and boast 97% design efficiency.
Supercapacitors for 48-volt system power storage
Eaton has a current portfolio of supercapacitors for use in commercial vehicle applications, including 48V commercial vehicle systems. In addition, Eaton is developing advanced technology to further increase the level of power and energy storage capacity in these products.
Supercapacitors can quickly charge and discharge at higher rates than lithium-ion batteries. While the size and weight are comparable to lithium-ion packs, supercapacitors don't retain high levels of energy in comparison, do not require a liquid cooling system and have a longer cycle life.
Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. Eaton is guided by its commitment to do business right, to operate sustainably and to help its customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, Eaton is accelerating the planet's transition to renewable energy, helping to solve the world's most urgent power management challenges, and doing what's best for its stakeholders and all of society.
Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005013/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom